Open AccessAssessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI
Author(s) -
A.M. Starzer,
Anna S. Berghoff,
Tatjana Traub-Weidinger,
Alexander Haug,
Georg Widhalm,
Marcus Hacker,
Ivo Rausch,
Matthias Preusser,
Marius E. Mayerhoefer
Publication year - 2021
Publication title -
clinical nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.637
H-Index - 57
eISSN - 1536-0229
pISSN - 0363-9762
DOI - 10.1097/rlu.0000000000003404
Subject(s) - medicine , nuclear medicine , lymphoma , lesion , concordance , pathology , in vivo , positron emission tomography , biology , microbiology and biotechnology
F-FDG PET is limited for assessment of central nervous system lymphoma (CNSL) due to physiologic tracer accumulation in the brain. We prospectively evaluated the novel PET tracer Ga-pentixafor, which targets the C-X-C chemokine receptor 4 (CXCR4), for lesion visualization and response assessment of CNSL.